Sanofi's $2.2 Billion Acquisition of Dynavax Boosts Vaccine Portfolio
Sanofi is acquiring U.S. biotech Dynavax for $2.2 billion to expand its adult vaccine portfolio, including hepatitis B and shingles vaccines, aiming to diversify and boost revenue growth amid regulatory and market pressures. The deal, expected to close in early 2026, also includes an experimental shingles vaccine with potential long-term sales, while Sanofi faces setbacks with an FDA rejection of its multiple sclerosis drug.